If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
118
results.
Updated on
28/08/2025 [07:01:00]
Absstract of: EP4606303A1
Glucose and ketones may be dysregulated singularly or concurrently in certain physiological conditions and may be advantageously assayed together using an analyte sensor capable of detecting both analytes. Certain analyte sensors capable of dual detection may comprise a first working electrode and a second working electrode, a ketones-responsive active area disposed upon a surface of the first working electrode, a glucose-responsive active area comprising a glucose-responsive enzyme disposed upon a surface of the second working electrode, a membrane having a first portion overcoating the ketones-responsive active area and a second portion overcoating the glucose-responsive active area, in which the first portion and the second portion have different compositions. The ketones-responsive active area comprises an enzyme system comprising at least two enzymes that are capable of acting in concert to facilitate detection of ketones.
Absstract of: US2025261885A1
Methods, computers, and systems used to improve accuracy of glucose level measurement of an in vivo positioned sensor are disclosed herein. The method includes collecting signal data from an in vivo positioned sensor over a period of time, wherein the signal data is indicative of glucose levels, analyzing the collected signal data and identifying signal data points that occur most frequently within the collected data, correlating the identified signal data points to a normal physiological level for glucose, the identified signal data points being taken from the signal data collected from the in vivo positioned sensor, and deriving glucose levels from the collected signal data using the identified signal data points as a reference point for the normal physiological level of the glucose for a user of the in vivo positioned sensor
Absstract of: US2025262379A1
Exemplary embodiments relate to drug delivery devices, such as automated insulin delivery (AMD) devices. The described methods and apparatuses allow an AMD device to be initialized and/or operated with little or no user input. Exemplary logic initializes the AMD device to operate with known-safe drug delivery parameters that leverage the AMD device's ability to monitor blood glucose levels at short intervals and continuously deliver small amounts of insulin. The AMD then rapidly adapts the parameters and system constraints based on current and historical glucose measurements. Further embodiments provide for the detection of events that result in disturbances to glucose control, and to adaptation of alert frequency based on user behavior.
Absstract of: US2025266143A1
Systems and methods are disclosed that provide smart alerts to users, e.g., alerts to users about diabetic states that are only provided when it makes sense to do so, e.g., when the system can predict or estimate that the user is not already cognitively aware of their current condition, e.g., particularly where the current condition is a diabetic state warranting attention. In this way, the alert or alarm is personalized and made particularly effective for that user. Such systems and methods still alert the user when action is necessary, e.g., a bolus or temporary basal rate change, or provide a response to a missed bolus or a need for correction, but do not alert when action is unnecessary, e.g., if the user is already estimated or predicted to be cognitively aware of the diabetic state warranting attention, or if corrective action was already taken.
Absstract of: US2025267580A1
A battery-powered infusion pump for medicament delivery (e.g., insulin) may collect and store data related to the pump. The infusion pump can communicate some or all of the stored data to another device and control the timing and amount of data communicated in order to conserve battery life.
Absstract of: US2025261881A1
A glucose sensor is configured to be wrapped around a surface of an injection needle or cannula. The glucose sensor measures a glucose concentration of a patient when the injection needle or cannula is inserted into the patient. The glucose sensor includes a flexible substrate, at least two electrodes disposed on a surface of the flexible substrate, a glucose-responsive hydrogel at least partially disposed on a first electrode of the at least two electrodes, and a membrane permeable to glucose. The membrane is disposed on the glucose-responsive hydrogel. The total thickness of the glucose sensor is less than 10 pm.
Absstract of: US2025266171A1
A blood glucose prediction method includes training a prediction model; receiving a first data set of an object; when a first data type is a label, updating a personalized database; counting the personalized data records to generate a first total number; if the first total number is greater than or equal to a first threshold value, screening personalized data calibrated records; if the first total number is equal to a second threshold value, training a personalized prediction model; when the first data type is a prediction, counting the personalized data records to generate a second total number; if the second total number is smaller than the second threshold value, based on the prediction model, making a prediction; and if the second total number is equal to the second threshold value, based on the prediction model and the personalized prediction model, making a personalized prediction.
Absstract of: WO2025175025A1
A casing for an insulin delivery system includes a housing, a lid, and a gasket. The housing includes a first overmolded rubber member defining a first channel part. The lid includes a second overmolded rubber member defining a second channel part. The lid is couplable to the housing to define an enclosure and a cavity. The enclosure is configured to receive an insulin pump. The cavity receives the rubber members such that the channel parts define a channel when the lid is removably coupled to the housing. The channel encloses a tubing to fluidly couple the insulin pump to an outside of the casing. The gasket is received between the housing and the lid to seal the housing with the lid, preventing fluid ingress into the cavity and the enclosure and providing a waterproof seal between the cavity and the enclosure when the lid is removably coupled to the housing.
Absstract of: US2025262381A1
A method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (PWD). The method may also include modifying the baseline basal insulin rate stored in the memory for a second diurnal time period that is at least 20 hours after the first diurnal period based on an amount of insulin actually delivered during the first diurnal time period.
Absstract of: WO2024077402A1
The present disclosure provides a matrix microneedle patch made of a hyaluronic acid (HA) polymeric backbone functionalized with dopamine (DA) and 4-amino-3-fluorophenylboronic acid (AFBA, pKa ~7.5) that quickly and spontaneously crosslinks upon mixing of the polymer solutions by auto-oxidation of catechol groups and reversible interactions between AFBA and catechol functional groups in the absence of any chemical crosslinking agent. The DA and AFBA content were selected for conjugation into the backbone of the HA polymer for the desired hormone delivery profile. The patch provides high drug loading capacity for long-term drug delivery application. The crosslinking mechanism for microneedle fabrication is biocompatible and beneficial for sustaining hormone drug stability and bioactivity as it does not require harsh crosslinking conditions. Facile pH adjustment of the matrix hydrogel can be easily casted into a microneedle patch without multistep processes that conventional patch polymerization requires. The present matrix microneedle patch demonstrates sufficient skin penetration, rapid swelling in interstitial media, high drug loading capacity and effective hypo/hyperglycemia prevention by the automated hypo/hyperglycemia-triggered delivery of hormones through the skin.
Absstract of: EP4603003A2
Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycaemic-regulation therapies. To define those outcome metrics, frequent Blood Glucose (BG) reference measurements are still needed, with consequent relevant difficulties in outpatient settings. Here we propose a "retrofitting" algorithm that produces a quasi continuous time BG profile by simultaneously exploiting the high accuracy of available BG references (possibly very sparsely collected) and the high temporal resolution of CGM data (usually noisy and affected by significant bias). The inputs of the algorithm are: a CGM time series; some reference BG measurements; a model of blood to interstitial glucose kinetics; and a model of the deterioration in time of sensor accuracy, together with (if available) a priori information (e.g. probabilistic distribution) on the parameters of the model. The algorithm first checks for the presence of possible artifacts or outliers on both CGM datastream and BG references, and then rescales the CGM time series by exploiting a retrospective calibration approach based on a regularized deconvolution method subject to the constraint of returning a profile laying within the confidence interval of the reference BG measurements. As output, the retrofitting algor
Absstract of: GB2638147A
A system 100 comprises a number of devices 102 in communication with one another. The devices 102 are associated with a user 104 and may comprise a smartphone 102A, wearable devices such as a headset 102B or heart rate monitor 102C, and other local devices 102D,102E such as smart speakers including a microphone, cameras, motion sensors or other devices used for monitoring the area around the user 104. The wearable devices may comprise sensors for monitoring physiological parameters or an IMU for monitoring position or movement of the user 104. One or more of the devices 102 can be configured to detect a critical event. A critical event is an event considered to be dangerous or causes the user to require assistance such as cardiac events, a drop in blood sugar level, or a fall. If a critical event occurs, one or more of the devices 102 can raise an alarm or contact assistance. Before such takes place, the system confirms that a prospective critical event is an actual critical event by obtaining additional data from another device 102 in the system. This can help to avoid false alarms or other calls for assistance being raised unnecessarily.
Absstract of: EP4604136A1
A method performed by an electronic apparatus is disclosed. The method comprises receiving information about a user's glucose concentration from an analyte monitoring device attached to the user's body, receiving an alert condition set by a follower of the user at the follower's device, determining whether the alert condition is satisfied based on the information about the user's glucose concentration, and controlling the follower's device to output an alert when the alert condition is satisfied.
Absstract of: US2025259727A1
Disclosed is a meal detection and meal size estimation machine learning technology. In some embodiments, the techniques entail applying to a trained multioutput neural network model a set of input features, the set of input features representing glucoregulatory management data, insulin on board, and time of day, the trained multioutput neural network model representing multiple fully connected layers and an output layer formed from first and second branches, the first branch providing a meal detection output and the second branch providing a carbohydrate estimation output; receiving from the meal detection output a meal detection indication; and receiving from the carbohydrate estimation output a meal size estimation.
Absstract of: US2025259720A1
This disclosure relates to a method, a mobile device, and a computer program, for managing medical data such as, e.g., glucose concentrations, by an electronic disease management system. In the method a change of the local time between generation of a first set of medical data and a second set of medical data is detected.
Absstract of: AU2024219128A1
Disclosed herein are intravascular artificial pancreas devices and methods for their manufacture.
Absstract of: LU600247B1
The invention belongs to the technical field of pressure monitoring, in particular to a blockage detection device for a diabetic insulin injection pump, which comprises a gun shell, wherein an injection refill is arranged in the barrel of the gun shell, a refill piston is arranged in the injection refill, an injection pipeline is arranged at one end of the injection refill near the muzzle of the gun shell, the injection pipeline extends out of the gun shell; one side of the refill piston near the injection pipeline is provided with a membrane pressure sensor, a driving mechanism for driving the refill piston to move is arranged inside the gun body of the gun shell; a handle of the gun shell is provided with a manual switch assembly, a controller, a blood sugar monitoring module and an alarm prompt system.
Absstract of: US2025255561A1
A method performed by an electronic apparatus is disclosed. The method comprises receiving information about a user's glucose concentration from an analyte monitoring device attached to the user's body, receiving an alert condition set by a follower of the user at the follower's device, determining whether the alert condition is satisfied based on the information about the user's glucose concentration, and controlling the follower's device to output an alert when the alert condition is satisfied.
Absstract of: US2025256027A1
The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include receiving and/or determining one or more user specific dosage parameters.
Absstract of: EP4601218A2
A system is provided for monitoring analyte in a host, including a continuous analyte sensor that produces a data stream indicative of a host's analyte concentration and a device that receives and records data from the data stream from the continuous analyte sensor. In one embodiment, the device includes a single point analyte monitor, from which it obtains an analyte value, and is configured to display only single point analyte measurement values, and not any analyte measurement values associated with data received from the continuous analyte sensor. Instead, data received from the continuous analyte sensor is used to provide alarms to the user when the analyte concentration and/or the rate of change of analyte concentration, as measured by the continuous analyte sensor, is above or below a predetermined range. Data received from the continuous analyte sensor may also be used to prompt the diabetic or caregiver to take certain actions, such as to perform another single point blood glucose measurement. In another embodiment, the device provides for toggling between two modes, with one mode that allows for display of glucose concentration values associated with the continuous glucose sensor and a second mode that prevents the display of glucose concentration values associated with the continuous glucose sensor.
Absstract of: EP4599864A2
Infusion systems, infusion devices, and related operating methods are provided. An exemplary method of operating an infusion device (100, 500) to deliver fluid to a body of a user involves obtaining measurement values for a physiological condition influenced by the fluid, autonomously operating the infusion device to deliver the fluid based at least in part on the measurement values, and detecting a nonactionable condition based on the measurement values. In response to detecting the nonactionable condition, delivery of the fluid is limited while maintaining autonomous operation of the infusion device. In one exemplary embodiment, the nonactionable condition is a rescue condition indicative of the user having consumed fast-acting carbohydrates, and thus insulin delivery may be automatically limited in response to detecting the rescue carbohydrate consumption.
Absstract of: WO2024077303A2
Glucose systems that include a minimally invasive scalp-worn device that includes first and second sensors. The systems are adapted to determine one or more glucose states based on sensed EEG signals using the scalp-worn device.
Absstract of: EP4601278A2
Method, device and system for providing consistent and reliable glucose response information to physiological changes and/or activities is provided to improve glycemic control and health management.
Absstract of: EP4599866A2
An infusion pump system is disclosed for dispensing liquid medication, such as insulin. The infusion pump system includes a first reservoir for storing liquid medication, a first fluid driver for exerting pressure on the first reservoir, a second reservoir for storing liquid medication, and a second fluid driver for exerting pressure on the second reservoir. One or more valves are used to permit flow of liquid medication from the first reservoir to the second reservoir, and to permit flow of liquid medication from the second reservoir to an infusion site. Each of the valves is selectively opened or closed to fill the second reservoir with liquid medication from the first reservoir and to dispense liquid medication from the second reservoir to the infusion site. A controller and one or more sensors are used to monitor and control the system.
Nº publicación: US12383675B1 12/08/2025
Applicant:
PACIFIC DIABETES TECH INC [US]
Pacific Diabetes Technologies Inc
Absstract of: US12383675B1
In an aspect, the present disclosure provides a method comprising: (a) positioning an insulin delivery device on a body of a subject via a single puncture site in said body of said subject; (b) using said insulin delivery device to deliver an insulin or insulin analog formulation to said subject via said single puncture site; and (c) using a sensor of said insulin delivery device to measure a glucose concentration in said body of said subject via said single puncture site, wherein (b) and (c) are performed at substantially the same time for a time period of at least 1 hour subsequent to said positioning in (a), while maintaining a sensitivity of said sensor of at least 50% of an initial sensitivity of said sensor.
BOPI
Electronic site
